FDA Regulatory Pathways for AI Medical Devices in 2026 — TEMPO Pilot and Generative AI Framework (Updated)
CONCEPTThe FDA has established multiple regulatory pathways for AI-enabled medical devices, including the TEMPO (Total Product Life Cycle Advisory for Modular and Operable) pilot program for generative AI devices. The TEMPO pathway allows manufacturers to bring generative AI devices to patients before full pre-market authorization, with post-market surveillance and adaptive governance frameworks. The agency has also released guidance on regulatory frameworks for generative AI-enabled medical devices, emphasizing risk-based classification, transparency requirements, and ongoing performance monitoring. FDA distinguishes between deterministic AI systems (traditional machine learning) and generative AI systems, applying different oversight standards to each. However, significant gaps remain between FDA guidance and actual regulatory practice. State regulators and health systems are moving faster than FDA approval timelines, creating de facto regulatory fragmentation. Additionally, the Trump administration's deregulation agenda may reduce FDA oversight intensity, creating uncertainty about enforcement priorities. Healthcare organizations should track FDA guidance updates closely, engage with state regulatory sandboxes cautiously, and maintain awareness of evolving federal-state regulatory conflicts. The regulatory landscape for AI medical devices remains fluid and subject to political change. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.